Related references
Note: Only part of the references are listed.Predictive Biomarkers in Prostate Cancer: Is It Time To Go All In on Liquid Biopsies?
Mayuko Kanayama et al.
EUROPEAN UROLOGY (2020)
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
Cameron Herberts et al.
EUROPEAN UROLOGY (2020)
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
Heidi Fettke et al.
EUROPEAN UROLOGY (2020)
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Manish Kohli et al.
EBIOMEDICINE (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer
David T. Miyamoto et al.
EUROPEAN UROLOGY (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Clare Gilson et al.
JCO PRECISION ONCOLOGY (2020)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
Philipp Nuhn et al.
EUROPEAN UROLOGY (2019)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
Ariella B. Hanker et al.
CANCER DISCOVERY (2019)
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer
Bram De Laere et al.
JAMA ONCOLOGY (2019)
Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer
Chiang-Ching Huang et al.
CANCERS (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Bram De Laere et al.
CLINICAL CANCER RESEARCH (2019)
Multiparametric liquid biopsy analysis in metastatic prostate cancer
Emmanuelle Hodara et al.
JCI INSIGHT (2019)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise
Semini Sumanasuriya et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Alexander W. Wyatt et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
David A. Quigley et al.
CELL (2018)
The long tail of oncogenic drivers in prostate cancer
Joshua Armenia et al.
NATURE GENETICS (2018)
Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients
Manish Kohli et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
Helen B. Pearson et al.
CANCER DISCOVERY (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
Semini Sumanasuriya et al.
EUROPEAN UROLOGY ONCOLOGY (2018)
Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns
Bram De laere et al.
EUROPEAN UROLOGY (2017)
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer
Matti Annala et al.
EUROPEAN UROLOGY (2017)
Cancer DNA in the Circulation The Liquid Biopsy
Hatim Husain et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer
Young Kwang Chae et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson et al.
NATURE COMMUNICATIONS (2017)
AR Signaling and the PI3K Pathway in Prostate Cancer
Megan Crumbaker et al.
CANCERS (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
Clonal origin and spread of metastatic prostate cancer
Jamie L. van Etten et al.
ENDOCRINE-RELATED CANCER (2016)
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Akash Kumar et al.
NATURE MEDICINE (2016)
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Alexander W. Wyatt et al.
JAMA ONCOLOGY (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
Roberta Ferraldeschi et al.
EUROPEAN UROLOGY (2015)
The evolutionary history of lethal metastatic prostate cancer
Gunes Gundem et al.
NATURE (2015)
Plasma AR and abiraterone-resistant prostate cancer
Alessandro Romanel et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer
Shu Xia et al.
ONCOTARGET (2015)
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context
Fabienne Schmit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
Himisha Beltran et al.
EUROPEAN UROLOGY (2013)
Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention
Shidong Jia et al.
CANCER DISCOVERY (2013)
Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor
Inma M. Berenjeno et al.
BIOCHEMICAL JOURNAL (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
Jing Ni et al.
CANCER DISCOVERY (2012)
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
David J. Mulholland et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
Wennuan Liu et al.
NATURE MEDICINE (2009)
Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis
Shidong Jia et al.
NATURE (2008)
PTEN-deficient cancers depend on PIK3CB
Susan Wee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Share Paper
